Form 4: FibroGen CEO Wettig Thane Reports Stock Transaction
SEC Form 4 Filing
FibroGen CEO Wettig Thane reports the disposal of 20,840 shares to cover tax obligations and maintains beneficial ownership of 448,556 shares.
Summary
- On May 1, 2024, FibroGen CEO Thane Wettig disposed of 20,840 shares of common stock to satisfy a tax obligation.
- The transaction was executed at a price of $1.17 per share.
- Following the transaction, Wettig directly owns 448,556 shares of FibroGen common stock.
- Wettig also indirectly owns 1,000 shares through a spouse.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports a stock transaction related to tax obligations, which is a routine event.
Industry Context
Form 4 filings are standard disclosures required by the SEC for company insiders, providing transparency into their trading activities. This filing indicates the CEO's stock transactions, which investors often monitor for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in the CEO's holdings, but it is primarily driven by tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | Date of stock transaction (disposal of shares). |
| 05/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.